All In Biotech

Drug Trial Radar · NCT02419417

Study of BMS-986158 in Subjects With Select Advanced Cancers

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

83

Actual

Start

Jun 19, 2015

Primary completion

Mar 17, 2021

Study completion Mar 17, 2021

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

Conditions

  • Advanced Tumors

Interventions

  • BMS-986158Drug

    Specified dose on specified days

  • NivolumabBiological

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse EventsTime frame: From first dose to 30 days following last dose (up to approximately 29 months)
  2. Number of Participants With Abnormal Hepatic Test ValuesTime frame: From first dose to 30 days following last dose (up to approximately 29 months)

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • City Of Hope National Medical Center

    Duarte, California

  • University Of Colorado

    Aurora, Colorado

  • Dana Farber Cancer Institute.

    Boston, Massachusetts

  • Oregon Health & Science University

    Portland, Oregon

  • Univ. Of Pa

    Philadelphia, Pennsylvania

  • Institute for Translational Oncology Research-ITOR

    Greenville, South Carolina

  • Nucleus Network

    Melbourne, Victoria, Australia

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Local Institution

    Lyon, France

  • Local Institution

    Villejuif, France

  • H. Univ. Vall dHebron

    Barcelona, Spain

  • Centro Integral Oncologico Clara Campal

    Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.